Transcutaneous Auricular Vagus Enhanced Recovery in the NeuroICU
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorWashington University School of Medicine
About this trial
This study will demonstrate the impact of taVNS on reducing adverse events in NeuroICU patients, determine if taVNS reduces length of stay, and quantify the economic benefits of taVNS implementation in a broader neurocritical care population.
Eligibility criteria
Qualifiers
Age ≥18
Admission to the NeuroICU within 36 hours of onset of an acute medical condition.
Patient or authorized legal representative should be able to provide consent within 36 hours of ICU arrival
Glasgow Coma Scale GCS >3 & <= 12 at admission
Disqualifiers
Systemic immunosuppression
Receiving ongoing cancer therapy
Implanted electrical device (e.g., pacemaker, stimulator)
Bradycardia on admission (Sustained bradycardia on arrival with a heart rate < 50 bpm for >5 minutes)
Trial design
Treatments tested in this trial
- Auricular Vagus Nerve Stimulation
- Sham Auricular Vagus nerve Stimulation
Treatment groups
160 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov